AbbVie is a US pharmaceutical company that was spun off from Abbott in 2013. Its focus areas are immunology (Skyrizi, Rinvoq, formerly Humira), cancer drugs, neuroscience and aesthetic medicine with Botox. Its medicines are sold worldwide. As of Oct 11, 2026
According to the company, it is a global research-based biopharmaceutical company with a single business segment. Its therapeutic areas are immunology, neuroscience, oncology and aesthetics. Immunology includes Skyrizi, approved among other uses for moderate to severe plaque psoriasis, and Rinvoq, approved among other uses for rheumatoid arthritis. In neuroscience the company markets Vraylar for schizophrenia and Botox Therapeutic, for example for chronic migraine. Important customers also include managed care providers such as pharmacy benefit managers, as well as hospitals and government bodies such as the Medicaid programs; external partners handle parts of manufacturing.
Automatically summarized from SEC annual report (10-K, filed Feb 20, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026
Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
No buy zone
There is currently no buy zone for this symbol under our Elliott rule. One only forms when the price pulls back after a strong rise.
An observation, not investment advice
Timeframe 1 week · As of Oct 23, 2026 · display only, the rule works on 4-hour candles
Elliott count: Flat (regular), Corrective pattern (downward), C complete (2 of 3 guidelines) · B = 94% of A; C = 138% of A
Note: Structure ambiguous: leg C can also be read as three- or five-part.
Note: Count questionable: C in progress at 284% (C of A, limit 261.8%).
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
No buy zone of the rule on this timeframe – the chart shows only the Elliott count from the completed weekly candles (recalculated every day). Not a recommendation, not investment advice. Without a buy zone there is no reference for percentages – so no value axis and no prices; measurements are ratios of wave lengths.
Timeframe 1 day · As of Oct 26, 2026 · display only, the rule works on 4-hour candles
Elliott count: Nested combination, Corrective pattern (upward), Z in progress (1 of 3 guidelines) · X = 34% of W; Y = 34% of W; X = 78% of Y; Z = 59% of W–Y
provisional count The inner sub-waves cannot be seen on this timeframe – the hard Elliott rules are met, the internal structure remains open. Provisional – check the count yourself on the chart.
Note: Nested: leg Y is itself a combination, its X is 54.0% (at most 88.7%).
Note: Structure ambiguous: leg W can also be read as three- or five-part.
Note: Structure open: leg X cannot be broken down into sub-waves on this timeframe – provisional, check the count yourself on the chart.
Note: Count questionable: Y in progress at 173% (Y of W, limit 161.8%).
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
No buy zone of the rule on this timeframe – the chart shows only the Elliott count from the completed daily candles (recalculated every day). Not a recommendation, not investment advice. Without a buy zone there is no reference for percentages – so no value axis and no prices; measurements are ratios of wave lengths.
Timeframe 4 hours · As of Oct 27, 2026
Elliott count: Nested combination, Corrective pattern (upward), Z in progress (3 of 3 guidelines) · X = 51% of W; Y = 148% of W; X = 40% of Y; Z = 25% of W–Y
smaller wave degree Smaller wave degree: more sensitive turning-point detection, because no count fits at the usual degree – it describes shorter swings. Provisional – check the count yourself on the chart.
Note: Nested: leg W is itself a combination, its X is 38.3% (at most 88.7%).
Note: Structure ambiguous: leg Y can also be read as three- or five-part.
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
No buy zone of the rule on this timeframe – the chart shows only the Elliott count from the completed 4-hour candles (recalculated every hour). Not a recommendation, not investment advice. Without a buy zone there is no reference for percentages – so no value axis and no prices; measurements are ratios of wave lengths.
Timeframe 1 hour · As of Oct 27, 2026 · display only, the rule works on 4-hour candles
Elliott count: Flat (type known only after C), Corrective pattern (upward), C in progress (1 of 3 guidelines) · B = 153% of A; C = 135% of A
Comparison: The rule treats the last rise as the possible start of an upward impulse (without checking its history and structure). The Elliott count reads it as the first leg A of a correction.
Note: Flat type (regular, expanded, running) can only be decided once C is complete.
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
Automated analysis (rule-based): the rule calculates waves and Fibonacci levels from the completed hourly candles; the chart is recalculated every hour. Not investment advice. On this timeframe the chart only shows the rule setup (swing detection 4 × ATR) – the rule itself works on 4-hour candles. Axis and values: distance from the top of the buy zone in %, no prices.
On phones the drawing toolbar is hidden – drawing works better on a desktop.
Timeframe 1 week · As of Oct 23, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario (2 of 3 guidelines, medium) · no alternative Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
As long as the weekly close stays above the end of C, this applies: flat countermove downward in three waves (Flat, regular), C complete – count points to rising prices.
Invalid if the weekly close is below the end of C
If that breaks, this count no longer applies. Currently no alternative that follows the rules.
Timeframe 1 day · As of Oct 26, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario (1 of 3 guidelines, weak) · no alternative Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
provisional count The inner sub-waves cannot be seen on this timeframe – the hard Elliott rules are met, the internal structure remains open. Provisional – check the count yourself on the chart. No visible sub-waves in: X.
As long as the daily close stays above the end of the second X, this applies: complex countermove upward (Nested combination), Z in progress – count points to rising prices.
Invalid if the daily close is below the end of the second X
If that breaks, this count no longer applies. Currently no alternative that follows the rules.
Watcher Fibonacci target zones and levels for this count – as a help for your own review – from Watcher.
Timeframe 4 hours · As of Oct 27, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario (3 of 3 guidelines, strong) · no alternative Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
smaller wave degree Smaller wave degree: more sensitive turning-point detection, because no count fits at the usual degree – it describes shorter swings. Provisional – check the count yourself on the chart.
As long as the 4-hour close stays above the end of the second X, this applies: complex countermove upward (Nested combination), Z in progress – count points to rising prices.
Invalid if the 4-hour close is below the end of the second X
If that breaks, this count no longer applies. Currently no alternative that follows the rules.
Watcher Fibonacci target zones and levels for this count – as a help for your own review – from Watcher.
Timeframe 1 hour · As of Oct 27, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario (1 of 3 guidelines, weak) · no alternative Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
As long as the hourly close stays above the end of B, this applies: flat countermove upward in three waves (Flat, type known only after C), C in progress – count points to rising prices.
Invalid if the hourly close is below the end of B (−2.7% from the top of the zone)
If that breaks, this count no longer applies. Currently no alternative that follows the rules.
AbbVie · Sector Health Care · amounts in USD
Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 20, 2026.
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
70.2% Fiscal year 2025
Rank 80 of 100: higher than 80% of 153 peers (All). strong.
Rank 63 of 100: higher than 63% of 20 peers (Sector). medium.
Median Health Care: 66.6%
Share of revenue left after the direct cost of the products sold.
24.6% Fiscal year 2025
Rank 66 of 100: higher than 66% of 192 peers (All). medium.
Rank 68 of 100: higher than 68% of 20 peers (Sector). strong.
Median Health Care: 18.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
6.9% Fiscal year 2025
Rank 30 of 100: higher than 30% of 237 peers (All). weak.
Rank 33 of 100: higher than 33% of 26 peers (Sector). medium.
Median Health Care: 13.9%
Profit after all costs, interest and taxes divided by revenue.
3.2% Fiscal year 2025 (total assets at year end)
Rank 30 of 100: higher than 30% of 238 peers (All). weak.
Rank 17 of 100: higher than 17% of 26 peers (Sector). weak.
Median Health Care: 6.4%
Net income divided by total assets at fiscal year end.
−2.4% Fiscal year 2025
Rank 6 of 100: higher than 6% of 239 peers (All). weak.
Rank 17 of 100: higher than 17% of 26 peers (Sector). weak.
Median Health Care: 38.5%
Equity as a share of total assets. Usually low for banks.
29.1% Fiscal year 2025
Rank 82 of 100: higher than 82% of 213 peers (All). strong.
Rank 94 of 100: higher than 94% of 25 peers (Sector). strong.
Median Health Care: 14.9%
Free cash flow divided by revenue.
17.8B USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
+1.8% per year
Rank 23 of 100: higher than 23% of 230 peers (All). weak.
Rank 34 of 100: higher than 34% of 25 peers (Sector). medium.
Median Health Care: +5.6%
Average growth per year over 3 fiscal years.
+6.0% per year
Rank 25 of 100: higher than 25% of 217 peers (All). weak.
Rank 26 of 100: higher than 26% of 25 peers (Sector). weak.
Median Health Care: +8.5%
Average growth per year over 5 fiscal years.
+10.3% per year
Rank 65 of 100: higher than 65% of 157 peers (All). medium.
Rank 55 of 100: higher than 55% of 19 peers (Sector). medium.
Median Health Care: +10.1%
Average growth per year over 10 fiscal years.
−29.1% per year
Rank 4 of 100: higher than 4% of 157 peers (All). weak.
Rank 7 of 100: higher than 7% of 22 peers (Sector). weak.
Median Health Care: +5.5%
Growth of earnings per share per year, adjusted for stock splits.
−2.8% per year
Rank 9 of 100: higher than 9% of 146 peers (All). weak.
Rank 18 of 100: higher than 18% of 20 peers (Sector). weak.
Median Health Care: +7.0%
Growth of earnings per share per year, adjusted for stock splits.
−2.8% per year
Rank 8 of 100: higher than 8% of 140 peers (All). weak.
Rank 13 of 100: higher than 13% of 20 peers (Sector). weak.
Median Health Care: +8.3%
Growth of earnings per share per year, adjusted for stock splits.
282% Fiscal year 2025
Dividend per share divided by earnings per share.
+6.6% per year
Rank 32 of 100: higher than 32% of 118 peers (All). weak.
Rank 41 of 100: higher than 41% of 16 peers (Sector). medium.
Median Health Care: +7.8%
Growth of the dividend per share per year.
1.5x Fiscal year 2025
Free cash flow per share divided by dividend per share. From 1x the dividend is covered.
8 of 9 Fiscal year 2025
Rank 90 of 100: higher than 90% of 134 peers (All). strong.
Rank 92 of 100: higher than 92% of 19 peers (Sector). strong.
Median Health Care: 7.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
negative equity at fiscal year end
No rank: too few peers or not computed yet.
Long-term financial debt divided by equity.
0.67 at fiscal year end
Rank 7 of 100: higher than 7% of 215 peers (All). weak.
Rank 2 of 100: higher than 2% of 26 peers (Sector). weak.
Median Health Care: 1.56
Current assets divided by current liabilities.
+6.0% in 5 years
Rank 29 of 100: lower than 29% of 199 peers (All). weak.
Rank 6 of 100: lower than 6% of 24 peers (Sector). weak.
Median Health Care: −2.7%
Change in diluted share count. Negative = share buybacks, positive = new shares.
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 61.2B USD · Net income 4.2B USD · Net margin 6.9%
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Of 100 USD of revenue, 70.2 USD gross profit, 24.6 USD operating income and 6.9 USD net income remained.
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 61.2B USD | 100.0% |
| Gross profit | 43.0B USD | 70.2% |
| Cost of revenue | 18.2B USD | 29.8% |
| Operating income | 15.1B USD | 24.6% |
| Research & development | 9.1B USD | 14.9% |
| Other operating expenses | 18.8B USD | 30.7% |
| Net income | 4.2B USD | 6.9% |
| Interest expense | 2.9B USD | 4.7% |
| Taxes | 2.4B USD | 3.9% |
| Other | 5.6B USD | 9.1% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
The operating margin stayed roughly the same in 5 years (24.6%).
Gross marginOperating marginNet marginReturn on equity rose in 3 years from 35.3% to 46.9%.
Return on equityReturn on assets Return on equity hidden where equity is below 5% of total assets.The equity ratio fell in 5 years from 8.7% to −2.4%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.The current ratio fell in 5 years from 0.84 to 0.67.
Current ratioFree cash flow rose in 5 years from 16.8B USD to 17.8B USD.
Operating cash flowCapital expenditureFree cash flow in USDThe share count rose in 5 years by 6.0% – more new shares were issued than repurchased (dilution).
Diluted share countFrom annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
The dividend per share rose in 5 years from 4.84 USD to 6.65 USD.
Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.The payout ratio rose in 5 years from 177.9% to 281.8%.
Payout ratio (earnings)Payout ratio (free cash flow)Over 5 years, 59.6B USD went back to shareholders, 12% of it through share repurchases. That is 57% of the free cash flow of those years.
Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USDDividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
AbbVie next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
| Symbol | Revenue (FY) | Growth 5 yrs | Gross margin | Op. margin | Net margin | ROE | Equity ratio | FCF margin | Piotroski |
|---|---|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | 94.2B USD | +2.7% | 67.9% | – | 28.5% | 32.9% | 40.9% | 20.9% | 4/9 |
| HCA HCA Healthcare | 75.6B USD | +8.0% | – | – | 9.0% | – | −9.9% | 10.2% | – |
| LLY Lilly (Eli) | 65.2B USD | +21.6% | 83.0% | – | 31.7% | 77.8% | 23.6% | 13.8% | 7/9 |
| MRK Merck & Co. | 65.0B USD | +6.3% | 74.8% | – | 28.1% | 34.7% | 38.4% | 19.0% | 4/9 |
| PFE Pfizer | 62.6B USD | +8.5% | 74.3% | – | 12.4% | 9.0% | 41.5% | 14.5% | 6/9 |
| ABBV AbbVie this stock | 61.2B USD | +6.0% | 70.2% | 24.6% | 6.9% | – | −2.4% | 29.1% | 8/9 |
| BMY Bristol Myers Squibb | 48.2B USD | +2.5% | 71.1% | – | 14.6% | 38.2% | 20.5% | 26.7% | 8/9 |
| TMO Thermo Fisher Scientific | 44.6B USD | +6.7% | – | 17.4% | 15.0% | 12.6% | 48.4% | 14.1% | – |
| ABT Abbott Laboratories | 44.3B USD | +5.1% | 56.4% | 18.2% | 14.7% | 12.5% | 60.1% | 16.7% | 6/9 |
| Median of the sector 26 symbols | 44.4B USD | +8.5% | 66.6% | 18.0% | 13.9% | 14.3% | 38.5% | 14.9% | 7/9 |
Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).
Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
+6.0% per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 6.0% per year on average, but more slowly than the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
−1.7% per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: −2.8% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it fell by 1.7% per year on average. The median company in the sector reached +7.5% per year.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
6.9% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue, 6.91 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was 10.1%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
– latest balance sheet
Sector Health Care: median 0.66 (49 symbols)
What does this mean? Equity is negative (e.g. due to share buybacks). A debt-to-equity ratio cannot be formed meaningfully then.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
282% Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The payout was higher than the earnings per share; it is paid from cash flow, from reserves or with new debt. Median company in the sector: 28%.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
10 of 10 fiscal years with a profit
What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 61.2B | 4.2B | 6.9% | 2.36 | 6.65 | 282% |
| 2024 | Dec 31, 2024 | 56.3B | 4.3B | 7.6% | 2.39 | 6.29 | 263% |
| 2023 | Dec 31, 2023 | 54.3B | 4.9B | 9.0% | 2.72 | 5.99 | 220% |
| 2022 | Dec 31, 2022 | 58.1B | 11.8B | 20.4% | 6.63 | 5.71 | 86% |
| 2021 | Dec 31, 2021 | 56.2B | 11.5B | 20.5% | 6.45 | 5.31 | 82% |
| 2020 | Dec 31, 2020 | 45.8B | 4.6B | 10.1% | 2.72 | 4.84 | 178% |
| 2019 | Dec 31, 2019 | 33.3B | 7.9B | 23.7% | 5.28 | 4.39 | 83% |
| 2018 | Dec 31, 2018 | 32.8B | 5.7B | 17.4% | 3.66 | 3.95 | 108% |
| 2017 | Dec 31, 2017 | 28.2B | 5.3B | 18.8% | 3.30 | 2.63 | 80% |
| 2016 | Dec 31, 2016 | 25.6B | 6.0B | 23.2% | 3.63 | 2.35 | 65% |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q2/26 | Jun 30, 2026 | 17.0B | 3.6B | 21.3% | 2.03 | 1.73 | 85% |
| Q1/26 | Mar 31, 2026 | 15.0B | 695.0M | 4.6% | 0.39 | 1.73 | 444% |
| Q4/25 | Dec 31, 2025 | 16.6B | 1.8B | 10.9% | 1.02 | 1.73 | 170% |
| Q3/25 | Sep 30, 2025 | 15.8B | 186.0M | 1.2% | 0.10 | 1.64 | 1,640% |
| Q2/25 | Jun 30, 2025 | 15.4B | 938.0M | 6.1% | 0.52 | 1.64 | 315% |
| Q1/25 | Mar 31, 2025 | 13.3B | 1.3B | 9.6% | 0.72 | 1.64 | 228% |
| Q4/24 | Dec 31, 2024 | 15.1B | −22.0M | −0.1% | −0.02 | 1.64 | – |
| Q3/24 | Sep 30, 2024 | 14.5B | 1.6B | 10.8% | 0.88 | 1.55 | 176% |
| Q2/24 | Jun 30, 2024 | 14.5B | 1.4B | 9.5% | 0.77 | 1.55 | 201% |
| Q1/24 | Mar 31, 2024 | 12.3B | 1.4B | 11.1% | 0.77 | 1.55 | 201% |
| Q4/23 | Dec 31, 2023 | 14.3B | 822.0M | 5.7% | 0.46 | 1.55 | 337% |
| Q3/23 | Sep 30, 2023 | 13.9B | 1.8B | 12.8% | 1.00 | 1.48 | 148% |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $8.2M1 person | −$8.2M |
| 6 months | $00 people | $8.2M1 person | −$8.2M |
| 12 months | $00 people | $18.9M3 people | −$18.9M |
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
Latest news
No posts on ABBV yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules